Nexentis Technologies Inc. (NXTS)
NASDAQ: NXTS · Real-Time Price · USD
2.210
+0.200 (9.95%)
At close: Nov 13, 2026, 4:00 PM EST
2.270
+0.060 (2.71%)
Pre-market: Nov 16, 2026, 7:23 AM EST
Nexentis Technologies Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
642.37K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 263.00K | -131.00K | -33.25% |
| Dec 31, 2022 | 394.00K | -44.14K | -10.07% |
| Dec 31, 2021 | 438.14K | 205.87K | 88.63% |
| Dec 31, 2020 | 232.27K | 56.45K | 32.11% |
| Dec 31, 2019 | 175.82K | -250.77K | -58.78% |
| Dec 31, 2018 | 426.59K | 82.66K | 24.04% |
| Dec 31, 2017 | 343.93K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| The Mosaic Company | 11.90B |
| CF Industries Holdings | 7.94B |
| ICL Group | 7.77B |
| Corteva | 4.97B |
| The Scotts Miracle-Gro Company | 3.29B |
| FMC Corporation | 2.81B |
| CVR Partners | 659.46M |
| American Vanguard | 499.39M |
NXTS News
- 9 days ago - Nexentis Technologies Inc trading halted, news pending - TheFly
- 10 days ago - Nexentis Technologies announces one-for-five reverse stock split - TheFly
- 10 days ago - Nexentis Announces Reverse Stock Split - GlobeNewsWire
- 18 days ago - Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz - GlobeNewsWire
- 21 days ago - Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage - GlobeNewsWire
- 5 weeks ago - Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud - GlobeNewsWire
- 7 weeks ago - Nexentis Technologies appoints Major to Scientific Advisory Board - TheFly
- 7 weeks ago - Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board - GlobeNewsWire